iiinova — where your digital self keeps evolving

Reposted by Kathy D Miller, MD

American Cancer Society @americancancersoc.bsky.social · 30/05/2026

🏅 Congratulations to Dr. Nancy Davidson from @fredhutch.org on receiving 𝘁𝗵𝗲 𝗗𝗮𝘃𝗶𝗱 𝗞𝗮𝗿𝗻𝗼𝗳𝘀𝗸𝘆 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗼𝗳 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗔𝘄𝗮𝗿𝗱 from the American Society of Clinical Oncology (ASCO) and presenting her award lecture during this morning's Opening Session at #ASCO26.

162

Reposted by Kathy D Miller, MD

JCO Journals @jco-asco.bsky.social · 28/05/2026

High-impact research is a benchmark of success. Join JCO Journal editors for "The Ins and Outs of Medical Publishing" at #ASCO26: Friday, May 29 1 – 3:15 PM (CT) Room S103 Elevate your authorship skills and advance oncology. View the full schedule: bit.ly/4nGnIRf

012

Kathy D Miller, MD @kathydmillermd.bsky.social · 19/05/2026

Join JCO editors at ASCO26. We have one on one mentoring sessions available in the JCO central lounge

020

Kathy D Miller, MD @kathydmillermd.bsky.social · 06/06/2025

Still seats on the Pacer’s bandwagon if you’d like to jump on😀⛹🏻‍♂️

020

Reposted by Kathy D Miller, MD

MidwestHedonist @midwesthedonist.bsky.social · 03/06/2025

Spread the love and acceptance #pridemonth

3581998514801

Kathy D Miller, MD @kathydmillermd.bsky.social · 02/06/2025

Great time with early career attendees today at the JCO poster walk this morning The future of our field is indeed bright

030

Kathy D Miller, MD @kathydmillermd.bsky.social · 01/06/2025

Serena 6 AI PFS 9.2 mos + 6.3 mos (PFS 2nd line cami)= 15.5 Sounds like the 16 mos with early switch? I know…. Cross trial comparisons are hard but lead time bias is real

020

Kathy D Miller, MD @kathydmillermd.bsky.social · 01/06/2025

Have to ask how Serena 6 got into NEJM? PFS2 as defined is really PFS2 in control arm vs PFS3 in cami arm Uninterpretable and real potential that pts will move to chemo sooner than needed

020

Kathy D Miller, MD @kathydmillermd.bsky.social · 31/05/2025

My new favorite assessment The SMOG readability score SMOG = simple measure of gobbledygook Use it to determine the education level needed for comprehension

010

Kathy D Miller, MD @kathydmillermd.bsky.social · 31/05/2025

Shout out to Gilead and the Ascent 4 trial for providing an opportunity to crossover to pts randomized toTPC. Finally respect for pts who agree to participate

000

Kathy D Miller, MD @kathydmillermd.bsky.social · 31/05/2025

Stop by JCO central while at ASCO. Enjoy the coffee, meet the editors and staff, learn more about JCO

021

Kathy D Miller, MD @kathydmillermd.bsky.social · 11/12/2024

No questions allowed after the EMBER 3 presentation How is endocrine therapy alone SOC for the 40 percent with no prior CDKi exposure? When they amended to add illum plus abema arm they should have added SOC plus abema too Without that control, the data are impossible to interpret

040

Kathy D Miller, MD @kathydmillermd.bsky.social · 06/12/2024

It’s almost SABCS time. If your attending stop by poster session 1 to learn about epigenetic therapy plus PARPis… just to say hello

050

Kathy D Miller, MD @kathydmillermd.bsky.social · 22/11/2024

For the real testes cancer/Einhorn fans, the full event can be viewed here....you are responsible for your own tissues! www.youtube.com/watch?v=klOA...

youtube.com

Larry Einhorn: Celebrating 50 years of the cure

YouTube video by IU Simon Comprehensive Cancer Center

050

Reposted by Kathy D Miller, MD

Kathy D Miller, MD @kathydmillermd.bsky.social · 22/11/2024

It was an honor to celebrate Dr. Larry Einhorn and the 50th anniversary of the cure for testis cancer. Former patients, colleagues, trainees, and family all joined a special evening. You can catch a glimpse of the fun - if you know Larry, please send him a note www.youtube.com/watch?v=U2Iu...

youtube.com

Larry Einhorn: Celebrating 50 years of the cure

YouTube video by IU Simon Comprehensive Cancer Center

041

Kathy D Miller, MD @kathydmillermd.bsky.social · 22/11/2024

youtube.com

Larry Einhorn: Celebrating 50 years of the cure

YouTube video by IU Simon Comprehensive Cancer Center

041

Kathy D Miller, MD @kathydmillermd.bsky.social · 22/11/2024

Don't miss this rapid update to the ASCO Small Cell Lng Cancer guidelines sites.libsyn.com/115284/syste... Recently published results of the phase III ADRIATIC trial (consolidation durva) and the phase II DeLLphi-301 (tarlatamab) prompted this important update

sites.libsyn.com

ASCO Guidelines: Systemic Therapy for SCLC Rapid Update

Dr. Greg Kalemkerian reviews the latest evidence-based rapid update from the Expert Panel on systemic therapy for small cell lung cancer. He discusses the updated recommendations for patients with lim...

030